Skip to main content
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals — Investor Relations & Filings

Ticker · 2561 ISIN · KYG9363A1003 LEI · 254900OJ8HIP6GRV1044 HKEX Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-05-18 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2561

About VISEN Pharmaceuticals

http://www.visenpharma.com

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on the development and commercialization of paradigm-shifting therapies for endocrine diseases. The company is committed to addressing unmet medical needs within the Greater China market by providing innovative treatments and compassionate patient care. VISEN's core strategy involves leveraging advanced drug delivery platforms, which utilize prodrugs connected to carrier molecules via a linker structure. This technology enables the controlled, slow release of the unmodified prototype drug, ensuring sustained therapeutic action while the linker and carrier are safely excreted. VISEN serves as a key strategic partner for global biopharma companies seeking to commercialize high-quality endocrine assets in the region.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a regulatory “Next Day Disclosure Return” (Form FF305) required under the Hong Kong Main Board/GEM listing rules to report share repurchases and changes in treasury shares. It provides detailed transaction data for the company’s own share buyback, including dates, quantities, prices, and confirmations of compliance. This clearly matches the definition of a “Transaction in Own Shares” report (share repurchase/issuance).
2026-05-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-06 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026 AT 10:00 A.M.
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a Form of Proxy for the Annual General Meeting, including voting instructions and resolutions for shareholders to appoint proxies. This is a solicitation of proxy votes and provision of meeting materials, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-28 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice calling the Annual General Meeting of Visen Pharmaceuticals, listing agenda items, resolutions to be voted on, and proxy voting instructions. It is sent to shareholders to provide information and solicit their votes at the AGM. Therefore it falls under Proxy Solicitation & Information Statement (PSI), not the actual AGM materials or a post‐meeting voting results announcement.
2026-04-28 English
(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND SELL OR TRANSFER TREASURY SHARES; (3) PROPOSED RE-APPOINTMENT OF
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a shareholder circular and notice of the Annual General Meeting, outlining proposed resolutions (re-election of directors, share repurchase and issuance mandates, auditor reappointment) and enclosing the proxy form. It is clearly a proxy solicitation/information statement sent to shareholders to request their votes at the AGM, not the actual meeting transcript or financial report. Therefore, it best fits the Proxy Solicitation & Information Statement category.
2026-04-28 English
2025 Annual Report
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report' and covers the fiscal year ended December 31, 2025. It contains comprehensive sections including the CEO's statement, financial highlights, management discussion and analysis (MD&A), and audited financial statements (consolidated statement of profit or loss, financial position, etc.). It meets all criteria for a full annual report. FY 2025
2026-04-28 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.